The goal of this application is to test the hypothesis that a circulating inhibitor of vascular endothelial cell growth released by primary tumors inhibits the growth of metastases. The phenomenon of suppression of tumor growth by tumor mass is well-known, but a molecular mechanism has not been elucidated. Our preliminary data show that: (i) Primary mouse tumors inhibit growth of lung metastases; (ii) Removal of the tumor increases the number of visible metastases by 12-fold and the maximum size by 1000-fold; (iii) The suppression of metastatic growth appears to be due to inhibition of neovascularization and not to a direct inhibitory effect on the tumor cells; (iv) A specific inhibitor of endothelial proliferation has been isolated from serum and urine of tumor-bearing mice but not from mice with tumors removed. Tumor cells and other cell types are not inhibited. (v) The inhibitor has been purified from mouse urine as a 38 kD protein with an amino acid sequence homologous to an internal fragment of plasminogen, having an N-terminus at amino acid 98 and a predicted carboxy-terminus at amino acid 440, and named """"""""angiostatin."""""""" Full length plasminogen itself has no endothelial inhibitory activity. Human angiostatin co-purifies with murine angiostatin and the human cDNA has been cloned. Human angiostatin potently inhibits angiogenesis within lung metastases and growth of metastases.
Our Specific Aims are to: (1) Produce sufficient quantities of angiostatin; (2) Determine its therapeutic activity. (3) Initiate structure-activity studies of angiostatin by transfection of its cDNA and deletion mutants. (4) Identify and isolate the membrane receptor for angiostatin on vascular endothelial cells. Significance: These studies may provide: (i) A mechanism for suppression of metastasis by tumor mass; (ii) Additional direct evidence that tumor growth is angiogenesis-dependent; (iii) A novel method of discovering endogenous angiogenesis inhibitors; (iv) A possible new concept of tumor dormancy; (v) A potential new diagnostic and therapeutic approach in cancer patients.
|Lee, Tong-Young; Folkman, Judah; Javaherian, Kashi (2010) HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS One 5:e9945|
|Lee, Tong-Young; Muschal, Stefan; Pravda, Elke A et al. (2009) Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114:1987-98|
|Panigrahy, Dipak; Kaipainen, Arja; Huang, Sui et al. (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 105:985-90|
|Lee, Tong-Young; Tjin Tham Sjin, Robert M; Movahedi, Shahla et al. (2008) Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 14:1487-93|
|Kisucka, Janka; Butterfield, Catherine E; Duda, Dan G et al. (2006) Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A 103:855-60|
|Almog, Nava; Henke, Vanessa; Flores, Ludmila et al. (2006) Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 20:947-9|
|Tjin Tham Sjin, R M; Naspinski, J; Birsner, A E et al. (2006) Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619-27|
|Tjin Tham Sjin, Robert M; Satchi-Fainaro, Ronit; Birsner, Amy E et al. (2005) A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 65:3656-63|
|Celik, Ilhan; Surucu, Oguzkan; Dietz, Carsten et al. (2005) Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res 65:11044-50|
|Folkman, J; Ryeom, S (2005) Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol 70:389-97|
Showing the most recent 10 out of 28 publications